43 studies found for:    " March 26, 2008":" April 25, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Condition: HIV-Associated Lipodystrophy Syndrome
Interventions: Drug: Standard continuous antiretroviral therapy;   Drug: CD-4 guided therapy interruption;   Drug: Viral load driven treatment interruption
2 Unknown  Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone
Conditions: HIV Infections;   HIV-Associated Lipodystrophy Syndrome
Intervention:
3 Completed Sex, Aging and Antiretroviral Pharmacokinetics
Condition: HIV Infections
Intervention: Drug: ARV regimen chosen by treating physician
4 Completed Raltegravir as Early Therapy in African-Americans Living With HIV Study
Condition: HIV Infections
Intervention: Drug: Raltegravir + Truvada
5 Completed Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1;   Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2
6 Completed Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)
Condition: HIV Infections
Intervention: Drug: Lopinavir/ritonavir
7 Completed Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT
Conditions: HIV Infections;   Tuberculosis
Interventions: Device: QuantiFERON TB Gold In-Tube;   Device: T-SPOT.TB®
8 Active, not recruiting Prospective Observational Epidemiologic Study of Maraviroc's Safety
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
9 Completed
Has Results
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
Conditions: HIV Infections;   Cardiovascular Disease;   Insulin Resistance;   HIV Lipodystrophy;   The Metabolic Syndrome
Interventions: Drug: Pioglitazone;   Behavioral: Exercise Training
10 Recruiting Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)
Conditions: HIV-hepatitis Co-infection;   HIV Infections
Intervention:
11 Completed
Has Results
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
Condition: HIV Infections
Interventions: Drug: Raltegravir & Lopinavir/ritonavir;   Drug: Raltegravir and emtricitabine/tenofovir
12 Suspended Bioequivalence Study of Didanosine in Children Treated for HIV
Condition: HIV Infections
Intervention: Drug: didanosine
13 Completed
Has Results
Raltegravir Therapy for Women With HIV and Fat Accumulation
Conditions: HIV Infections;   Lipodystrophy
Intervention: Drug: raltegravir
14 Unknown  Effectiveness of Interactive Virtual Environment Games in Reducing Risky Sexual Behavior Among Men Who Have Sex With Men (The SOLVE-IT Study)
Condition: HIV Infections
Intervention: Behavioral: Socially Optimized Learning in a Virtual Environment (SOLVE)-IT
15 Completed Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: Emtricitabine/tenofovir disoproxil fumarate
16 Unknown  A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
Conditions: HIV Infections;   Hepatitis B Virus
Intervention:
17 Active, not recruiting Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon
Condition: HIV Infections
Interventions: Drug: Treatment initiation for HIV-1 group O infected patients;   Drug: Treatment initiation for HIV-1 group M infected patients
18 Completed TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
Condition: HIV
Intervention: Drug: TMC114; darunavir; Prezista
19 Completed Qualitative and Quantitative HIV RNA Detection in Saliva Using the Oragene RNA Kit
Condition: HIV Infections
Intervention:
20 Completed
Has Results
HIV Screening in the Emergency Department Setting
Condition: HIV Infections
Interventions: Other: Targeted Screening;   Other: Routine Screening

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years